logo
  Join        Login             Stock Quote

Insider Selling And Options Trading May Spell Troubles for Protalix (AMEX:PLX), (NASDAQ:OREX)

 February 02, 2011 11:30 AM
 


Small cap biotech investments with upcoming FDA catalysts has become one of the hottest new trends, especially due to the fact that it is easy to foresee or expect catalysts based on the use of FDA calendars, and general medical timelines on drug and clinical trials. Unlike other industries where new technologies in research and development are usually kept secret in order to deter competition, the biotech game is wide open as companies publicize their products from the very beginning all the way to marketing approval. This is because biotechs usually need on average $50-75 million dollars from a investigational new drug status all the way to completing phase I, II, and III trials and into marketing, thus they look to maximize their market caps earlier on based on hype in order to fund projects through share offerings.

[Related -iShares NASDAQ Biotechnology Index (ETF) (IBB): 3 Biotechs Up 132% In 2013 With Huge Upside Potential]

While many investors have become wealthy from multi-bagger gains by holding onto companies into PDUFA decisions, the grass isn't always greener on the other side. Such an example was witnessed on February, 1, 2011, where investors of Orexigen got burned by following highly bullish analyst reports, and an FDA panel vote which basically spelled out approval as a cake-walk. To the surprise of many investors, shares dropped 75% in the pre-market once a complete response letter declining marketing approval was received, and interestingly enough, Protalix seems to be following the same path as Orexigen. This is especially apparent when taking a look at the dramatic increase in share Protalix's price leading up to the FDA decision scheduled for February 25, 2011, while taking into consideration short interest, technical analysis and insider transactions.

[Related -Petrobras Puts And Calls In Play As Shares Drop After Q4 Earnings]

There is perhaps no better variable for predicting a company's future outlook than the vote of confidence from  one's own management gives through either the purchase or selling of shares. For many investors, both small and large, insider transactions via SEC forms has become almost like a magic 8 ball — providing direction and guidance, more often than not correctly, almost like a guiding light into the direction of the company. Despite this, it has become easy to get trapped in reading reports by mainstream media which concentrate on upcoming potentially positive FDA catalysts, often ignoring red flags such as high short interest, poor looking technicals, and insider transactions.

Orexigen's Fate Through The Eyes Of Insiders and Short Interest

Such a circumstance was seen most recently with shares of Orexigen (NASDAQ:OREX), whom saw its shares explode upwards from $4.50 all the way to a 52-week high of $11.15 almost overnight on a positive FDA panel vote which paved the way for what seemed a seemingly riskless investment into their February 1st PDUFA.


Next Page >>123
iOnTheMarket Premium
Advertisement

Advertisement


Comments Closed


rss feed

Latest Stories

article imageChart Says This Retailer's Comeback Isn't Finished

One of the surprises, at least on the surface, of the market's recent swoon was the outperformance of read on...

article imageETF Performance Review: Major Asset Classes | 19 Dec 2014

It’s all about real estate investment trusts (REITs) these days when it comes to bullish performance among read on...

article imageOil and Global Stock Markets Rebounding Sharply

So far so good on our expectation of a 4 to 5% pullback and then a resumption of the bull read on...

article imageGrading the FOMC

Love its members or loathe them, you have to admire the gradual impact the policy-making committee has had read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center

Related Articles:

Decent Monday Session
More Articles on: Medical



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.